SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SOM - SOMNOMED LIMITED

FNArena Sector : Medical Equipment & Devices

Year End: June

GICS Industry Group : Health Care Equipment & Services

Debt/EBITDA: -2.64

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.59 20 Feb 2025	0.005 OPEN $0.59	0.85% HIGH $0.59	18,474 LOW $0.59

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$0.59

20 Feb
2025

0.005

OPEN

$0.59

0.85%

HIGH

$0.59

18,474

LOW

$0.59

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . TRJ . UBI .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2019	2020	2021	2022	2023	2024
EPS Basic	xxx	xxx	xxx	xxx	xxx	-10.1
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	91.7 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	20.8
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	-6.3 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-13.36 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2019	2020	2021	2022	2023	2024
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-36.31 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-26.47 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-18.51 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-36.31 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-17.03 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-7.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2019	2020	2021	2022	2023	2024
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	3 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	4 M
Total Debt	xxx	xxx	xxx	xxx	xxx	7 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	6 M
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	16 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	1.21

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2019	2020	2021	2022	2023	2024
Capex	xxx	xxx	xxx	xxx	xxx	5.3 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	5.83 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	42 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	58 M
Research & Development	xxx	xxx	xxx	xxx	xxx	1 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Wilsons	29/01/2025	1	Overweight	$0.80	35.59%	Wilson raises its target for SomnoMed by 70% (not a typo) to 80c, maintaining its Overweight rating, citing a strong earnings (EBITDA) recovery and improved operational efficiency following last year’s restructuring. A 2Q trading update shows group revenue rising by 19% year-on-year to $53.7m, supported by a 37% increase in US sales and better manufacturing capacity, which helped recapture lost customers and reduce turnaround times, explains the broker. Revenue guidance remains at $105m, while EBITDA guidance has been raised to $7-9m from more than $7m. The broker notes ongoing demand growth in the global sleep apnoea market, bolstered by increased awareness and referrals, and sees the business benefiting from favourable sector tailwinds. FORECAST Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents. Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.70 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Wilsons

29/01/2025

Overweight

$0.80

35.59%

Wilson raises its target for SomnoMed by 70% (not a typo) to 80c, maintaining its Overweight rating, citing a strong earnings (EBITDA) recovery and improved operational efficiency following last year’s restructuring.

A 2Q trading update shows group revenue rising by 19% year-on-year to $53.7m, supported by a 37% increase in US sales and better manufacturing capacity, which helped recapture lost customers and reduce turnaround times, explains the broker.

Revenue guidance remains at $105m, while EBITDA guidance has been raised to $7-9m from more than $7m.

The broker notes ongoing demand growth in the global sleep apnoea market, bolstered by increased awareness and referrals, and sees the business benefiting from favourable sector tailwinds.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.70 cents.

Access Extra Coverage Research History >

SOM STOCK CHART

FNArena News on SOM

1	Australian Broker Call Extra Edition – Jan 29, 2025 Jan 29 2025 - Daily Market Reports

2	In Case You Missed It – BC Extra Upgrades & Downgrades – 06-12-24 Dec 06 2024 - Weekly Reports

3	Australian Broker Call Extra Edition – Dec 04, 2024 Dec 04 2024 - Daily Market Reports

4	Australian Broker Call Extra Edition – Oct 31, 2024 Oct 31 2024 - Daily Market Reports

5	Australian Broker Call Extra Edition – Sep 04, 2024 Sep 04 2024 - Daily Market Reports

Latest Medical Equipment & Devices News

1	Trend Remains Up For Catapult International Feb 18 2025 - Technicals

2	ESG Focus: Top ASX Companies, Superbugs & Hydrogen Feb 07 2025 - ESG Focus

3	ResMed Shakes Off GLP-1 Scare Feb 04 2025 - Australia

4	ResMed: Another Positive Quarterly Surprise? Jan 30 2025 - Australia

5	The Trend Remains Pro Medicus’ Friend Jan 16 2025 - Technicals

6	Diagnostic Imaging Radiates Opportunity Dec 18 2024 - Small Caps

7	ResMed’s Bounce-Back Complete Oct 29 2024 - Australia

8	Dr Boreham’s Crucible: Pro Medicus Sep 04 2024 - Australia

9	Pro Medicus: Don’t Stop Me Now Aug 20 2024 - Technicals

10	Dr Boreham’s Crucible: Blinklab May 20 2024 - Small Caps

1	Australian Broker Call Extra Edition – Jan 29, 2025 Jan 29 2025 - Daily Market Reports

2	In Case You Missed It – BC Extra Upgrades & Downgrades – 06-12-24 Dec 06 2024 - Weekly Reports

3	Australian Broker Call Extra Edition – Dec 04, 2024 Dec 04 2024 - Daily Market Reports

4	Australian Broker Call Extra Edition – Oct 31, 2024 Oct 31 2024 - Daily Market Reports

5	Australian Broker Call Extra Edition – Sep 04, 2024 Sep 04 2024 - Daily Market Reports

Get 2 Weeks free trial

Sign Up

Member Login

SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart